Introduction
Coronary artery disease remains a major cause of death and morbidity across the world, despite decreasing mortality rates in developed countries over the last decade. 1 Whereas the emergent management of ST elevation myocardial infarction (STEMI) is clear, non-ST elevation acute coronary syndromes (NSTEACS) are a more heterogeneous group, a fact that is reflected in their management. 2 Early risk stratification of patients admitted with NSTEACS is an important step in clinical assessment at the time of diagnosis, allowing
timely implementation of appropriate treatments. Early guidelines identified the highest risk MI population as patients with ongoing objective ischaemia and haemodynamic instability. 3, 4 Subsequent iterations added clinical risk stratification (CRS), utilizing varying combination of symptoms, co-morbidities, and objective data such as electrocardiogram (ECG) changes or cardiac biomarker elevation to determine risk. 5, 6 Further updates endorsed standardized risk assessment following the development and validation of risk stratification tools such as the Global Registry of Acute Coronary Events (GRACE) risk score (GRS) 7 or Thrombolysis in Myocardial Infarction (TIMI) risk score 8 ; the use of these tools is consistently recommended in contemporary major guidelines [9] [10] [11] [12] and may be better at predicting risk than clinical assessment. 13 Despite the evidence base and guidelines supporting objective assessment of risk in ACS, real-world uptake is unknown. Furthermore, a 'treatment-risk' paradox has been frequently observed, whereby those patients at objectively high risk of poor outcomes receive less aggressive therapy than lower risk subgroups. [14] [15] [16] [17] [18] Conversely, there also exists a misperception of risk, which may be contributed to by a preference for the use of subjective CRS rather than the use of validated risk tools such as the GRS. Consistent with this is the reported underestimation of true risk observed in physician-based assessments. 13, [19] [20] [21] [22] The aim of this study was to investigate the use and determinants of CRS in a NSTEACS cohort from 41 hospitals representing a diversity of facilities across Australia, the association between CRS stratification and treatment, the agreement between CRS and GRS, and the relative ability of the two risk stratification methods to predict inhospital and 6 month mortality.
Methods

Study design and population
The Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE) is an ongoing Australian registry that collects data on patients admitted with ACS to multiple centres across the country. The design and inclusion criteria have been previously described 23 and the number of participating sites has risen from 20 to 42 since inception. In brief, the first 10 consecutive patients admitted with ACS from the beginning of each month are recruited. All patients are required to have a presumed or definite diagnosis of ACS on presentation with symptoms consistent with acute ischaemia in addition to one of the following: ECG changes, elevated cardiac biomarkers (according to the local laboratory assay), documentation of coronary artery disease or two or more high risk clinical features [haemodynamic compromise, left ventricular ejection fraction (LVEF) <40%, diabetes or chronic kidney disease (CKD)]. Patients were excluded if there was a non-cardiac precipitant for ACS. Data collected include demographic and historical information, baseline clinical characteristics, investigations, and treatments. Hospital-level data available for analysis were bed capacity, urban or rural location, and the presence of a cardiac catheterization laboratory.
In addition, the study staff record whether there is evidence in the medical record that the patient was risk stratified by the medical team during admission. Patients were recorded as having undergone CRS if there was documentation of clinical risk in the notes, and if so, whether the patient was stratified as low, intermediate, or high risk. The method of this assessment (e.g. subjective determination or objective use of risk stratification tools) was not recorded in the case report form. Global
Registry of Acute Coronary Events risk score was retrospectively calculated where sufficient data were available; patients were classified as low (< _88), intermediate (89-118), or high risk (>118). 7 In-hospital outcomes included all-cause and cardiac death, myocardial infarction, heart failure, stroke, major bleeding, and acute kidney injury. Six-month outcomes were recorded by review of medical records and/or phone call followup, and included all-cause and cardiac death, hospital re-admission, myocardial infarction, heart failure, unplanned revascularization, recurrent angina, stent thrombosis, stroke, and major bleeding.
Ethics
Each participating centre received written Human Research Ethics Committee approval prior to commencement. 23 An opt-out consent process is permitted, including consent for follow-up.
Statistical analysis
Categorical variables are expressed as frequency and percentages. Continuous variables are presented as mean and standard deviation.
Comparison between groups was undertaken with an independent t-test for continuous variables and a v 2 test for categorical variables.
To determine the extent of the association between hospital and patient clinical factors and the binary outcome of undergoing CRS or not a multi-level logistic regression analysis was performed with the patient related factors at Level 1 and the hospitals at Level 2. Patient level variables with a P < 0.20 on univariable analysis were included in this model. These were age in quartiles, indigenous status, diagnosis, prior heart failure, prior peripheral vascular disease, prior stroke, prior myocardial infarction, prior percutaneous coronary intervention (PCI), prior coronary artery bypass graft (CABG), hypertension, hypercholesterolaemia, diabetes, CKD, heart rate in quartiles, Killip class, and elevated biomarkers. The multilevel model also generates the variance partition coefficient (VPC), which is the percent of the residual variation in the propensity to undergo a CRS that is attributable to unobserved hospital characteristics. To determine independent predictors of allocation to high CRS, multivariable logistic regression within the framework of generalized estimating equations was performed to correct for the bias in the estimation due to clustering by hospital.
The capacity of each tool to predict both in-hospital and 6 month mortality was determined by inputting the variables contributing to each into the appropriate mortality models and determining the c-statistic. Cohen's kappa 
coefficient was used to determine the agreement between the CRS and the GRS. A two-tailed probability value <0.05 was considered significant.
Statistical analysis was performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
Results
The study flow chart is shown in Figure 1 . From February 2009 to December 2015, 5991 patients with NSTEACS were enrolled in the CONCORDANCE registry. For this analysis, use (or non-use) of CRS was documented in 4512 patients for whom sufficient data for retrospective calculation of GRS were available (Cohort A). This cohort did not differ in baseline demographic or clinical characteristics from the overall CONCORDANCE NSTEACS population (data not shown). Nine hundred and twenty-seven (21%) of these had documentation of CRS use on admission (Cohort B). Cohort A was used to validate the predictive power of the GRS and to identify predictors for the use of CRS, while Cohort B was 
Determinants of the use of clinical risk stratification
Baseline patient characteristics for the included population according to whether or not they were risk stratified (Cohort A) are shown in Table 1 . Patients who underwent CRS were more likely to have a prior history of stroke, MI, or revascularization and were also more likely to have dyslipidaemia or a positive family history than those for whom CRS was not documented. Of note, patients who did not have CRS were more likely to have ischaemic ECG changes (47% vs. 37%, P < 0.001) and elevated biomarkers (81% vs. 65%, P < 0.001).
Multi-level analysis demonstrated that a family history of ischaemic heart disease was an independent predictor of CRS use, while dementia, ischaemic ECG changes, and elevated biomarkers were independent negative predictors of CRS use ( Table 2) .
There was important variation between sites in the documented use of CRS, from 0% to 86% of patients (Figure 2 ). In the majority of hospitals, risk status was recorded in less than 20% of enrolled patients. Patients were less likely to undergo CRS if presenting to an urban hospital [odds ratio (OR) 0.41, 95% CI 0.19-0.89]; bed capacity or the presence of a cardiac catheterization laboratory were not independent predictors of CRS use. The VPC in the multilevel model indicated that 22.2% of the residual variation in the propensity to undergo CRS is attributable to other unobserved hospital characteristics.
Clinical determinants of high clinical risk stratification risk
Compared to low-/intermediate-CRS risk, patients stratified as high CRS risk were more likely to have a history of prior MI, revascularization, and traditional cardiovascular risk factors ( Table 3) . Chronic kidney disease and malignancy were also more common in high CRS risk patients. The mean GRS was slightly higher in this group (102 ± 30 vs. 97 ± 27, P = 0.015). Importantly, of the clinical variables preponderance of high CRS risk allocation (67%), in comparison to a relatively even distribution of objective risk according to GRS (26% high risk). Within each CRS risk group, a large proportion of patients were inaccurately assigned risk as determined by GRS ( Figure 4 )-48% of low CRS risk patients had corresponding low GRS risk, while only 28% of high CRS risk patients were also high GRS risk. Consequently, there was poor agreement between CRS and GRS, with a kappa coefficient of 0.034. 
In-hospital and discharge treatments
Outcomes according to clinical risk stratification and Global Registry of Acute Coronary Events risk score risk tertiles
There were no differences in in-hospital MI/death, in-hospital death, or death at 6 months between low/intermediate and high CRS risk (Supplementary material online, Table S1 ). In contrast to this, patients at high risk according to GRS had significantly higher rates of all in-hospital major adverse cardiovascular events, including death cardiac death and death or MI, as well as 6 month mortality (Supplementary material online, Table S2 ). Clinical risk stratification showed significantly poorer discriminatory ability than GRS for the prediction of both in hospital (c-statistic 0.54 vs. 0.87, P < 0.0001) and 6 month (c-statistic 0.55 vs. 0.74, P = 0.01) death.
Discussion
Our key findings from this retrospective analysis of a multicentre national ACS registry are: (i) risk stratification for patients presenting with NSTEACS is underutilized; (ii) when performed and documented, assessment of high risk is clinically derived and driven by a prior history of ischaemic heart disease rather than known objective determinants of poor outcome; (iii) risk averse behaviour with regards to allocation of therapies is demonstrated in patients perceived to be at higher risk; and (iv) the methods of risk stratification as used in clinical practice agrees poorly with objective and validated risk scores and is not predictive of outcomes.
Use of risk stratification
Objective risk stratification allows expeditious and appropriate allocation of therapies and is recommended in major guidelines. However, documentation of risk status in the medical record was infrequent in our population and when used, appeared to be preferentially used in patients without objective evidence of an ACS (lack of ECG changes or troponin elevation). This suggests that CRS as documented in the medical record was serving as a surrogate of likelihood of disease 24, 25 and may have prompted clinicians to look more closely at these individuals. On the other hand, troponin elevation or ECG changes may be recognized as identifying a higher risk cohort and therefore documenting this in the medical record was regarded as superfluous. Indeed in the 2006 Australian ACS guidelines, a simplified risk algorithm was proposed incorporating three factors: the presence of chest pain, ECG changes, and biomarker elevation. However, individual patient factors only partly contributed to the documentation of risk, which varied greatly across the registry sites. Of the available hospital-level variables, a rural setting was the only independent predictor of CRS use. While risk assessment of inpatients is often essential to determine necessity and urgency of transfer in a rural setting, the problem identified in our study is that the CRS approach used to guide these decisions is likely to be the wrong tool.
Unknown hospital factors still accounted for 22.2% of the observed variation in CRS use between hospitals. A detailed site-level analysis was beyond the scope of this study, and as such the effects of other potentially important hospital-level factors such case volume, presence of a cardiology department and an established formal training programme for physician trainees were not able to be assessed.
Determinants of high clinical risk stratification
In addition to inconsistent documentation of risk, we found that determination of high risk was predicted predominantly by evidence of coronary disease. Although these variables may carry some prognostic value (for example, having >2 traditional cardiovascular risk factors is assigned 1 point in the TIMI risk score), the bulk of predictive power lies with other clinical features represented in the GRS, none of which predicted stratification as high risk by CRS. This highlights the relative subjectivity of CRS as compared to objective risk stratification with the GRACE score.
Risk of an adverse outcome-prognosis-may also be misinterpreted as the likelihood of a coronary cause for chest paindiagnosis. The former is the basis of the GRS. This distinction between prognosis and diagnosis is often blurred, particularly with the development of scores for patients presenting to the emergency department with chest pain. 26 The primary purpose of these algorithms is to identify patients who may or may not have an ACS and can be discharged safely from the emergency department. This approach is not a substitute for subsequent assessment of risk in patients admitted with confirmed ACS in whom prognosis guides inpatient therapy.
Indeed, these two processes should be quite distinct. 27 Clinical risk stratification and treatment strategies
The 'treatment-risk' paradox, whereby those patients at highest risk receive less aggressive therapy, has been observed and described in reported that patients perceived to be at higher risk still underwent more aggressive therapy. 20 An important distinction between the Canadian ACS 2 registry and CONCORDANCE that may contribute to this difference is that in the Canadian study, the treating physician for each patient completed a case report form that included CRS (low, intermediate, or high). 20 In CONCORDANCE, the treating physician was not obligated to complete a case report form or document CRS; this was obtained from inpatient notes by independent study investigators. Hence, our observational analysis provides a contemporary view of routine practice with a low likelihood of confounding by observer bias.
Correlation between clinical risk stratification and Global Registry of Acute Coronary Events risk score
Overall, there was poor correlation between CRS and GRS, a finding in concordance with Canadian data. 20 The GRS 28 identifies key clinical variables that carry the majority of prognostic value for mortality and recurrent MI. It has been validated in external registries 29 and indeed in our study predicted mortality with comparable discrimination to that observed in the original publications. In contrast, CRS displayed poor predictive ability with c-statistics only marginally greater than 0.5 for both in hospital and 6 month mortality-little better than that predicted by chance alone. This highlights the subjectivity of clinician-based CRS, as compared to objective GRS.
Limitations
This was an observational study based on nation-wide registry data. As with all such data, there may be inadequate accounting for all potential confounders, although registry data is often most representative of real-world practice. This analysis relied in part on the accurate documentation of CRS in the clinical notes; thus, the actual use of undocumented, informal risk stratification may be underestimated. The means of risk stratification, timing of risk stratification, and reason for risk group allocation in those who underwent CRS was not documented, although the poor agreement between CRS and GRS clearly demonstrates that an objective risk score was infrequently or inaccurately applied in most cases. Uncommon high-risk features or bleeding diatheses without a prior major bleed may have influenced risk assessment and treatment but not have been captured. The level of experience and training of the assessing doctor was not documented or mandated, which may have had a significant influence. Finally, a substantial percentage of the variation in CRS use was due to unobserved hospital-level factors that were not available for this analysis.
Conclusion
Objective risk stratification of patients with NSTEACS, although extensively validated and strongly recommended in all major guidelines, remains grossly underutilized in Australia. When implemented, risk stratification relies on clinical rather than objective criteria, correlates poorly with objective risk stratification, does not guide treatment and does not predict outcomes. There remains a significant need for improved understanding of risk assessment and application of objective risk determination in Australian contemporary practice.
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